News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Proposed combination enhances Pfizer’s position as a leading company in oncology
Subscribe To Our Newsletter & Stay Updated
